Erin D. McCaffery

FDA investigator

Appears on 4 documents from 2008 to 2011, mostly at sites in New Jersey. Most often cites postmarketing reporting of adverse drug experiences (21 CFR 314.80(b)).

4
Documents on file
4.5
Observations per 483
2008
First seen
2011
Most recent

What they cite most

From 9 observations

Activity by year

2008: 3, 2011: 1

Where

New Jersey 4

Is Erin D. McCaffery coming to your site?

Our team writes custom reports before an inspection: what this investigator cites most, how they write it up, and how your site's history compares, in one brief you can circulate.

Ask about any investigator in Claude or ChatGPT with the AI connector.

Inspection history

4 documents, newest first
FirmOpen
483 Actavis Elizabeth LLCApr 26, 2011 · Elizabeth, New Jersey
EIR McNeil PPC, Inc.Jul 31, 2008 · Parsippany, New Jersey
483 McNeil PPC, Inc.Jul 7, 2008 · Parsippany, New Jersey
EIR Actavis Totowa LLCMay 20, 2008 · Totowa, New Jersey

About this profile

What does Erin D. McCaffery inspect?

Erin D. McCaffery appears on 4 documents on file covering 3 sites, mostly in New Jersey.

What do they cite most often?

21 CFR 314.80(b) (postmarketing reporting of adverse drug experiences), followed by 21 CFR 820.100 and 21 CFR 211.110.

Can I read the observations?

Each document page previews the opening words of every observation. The full documents are available to buy, one at a time or together.

How current is this profile?

The most recent document on file for Erin D. McCaffery is dated Apr 26, 2011.